Sunday, 13 July 2025

Emerging Gene and Cell Therapy Strategies for Rare Pediatric Genetic Disorders | Chapter 2 | Microbiology and Biotechnology Research: An Overview Vol. 4

 

Gene therapy in paediatrics is an innovative treatment approach for addressing various genetic disorders that present in childhood. Gene and cell therapies have been developed and approved for a growing number of pediatric diseases, with ongoing research for additional innovative treatment options for the future. Each therapy is tailored to the specific disease and targets a specific genetic alteration or cell population. The development of new therapies is a complex and regulated process, with strict oversight at regional and European levels. Gene therapy has three facets such as, gene silencing using siRNA, shRNA and miRNA; gene addition introducing a functional gene that contains instructions for the cell to produce a specific protein; and finally gene editing based therapy where mutations are modified using specific nucleases such as zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and clustered regulatory interspaced short tandem repeats (CRISPR)/CRISPR-associated protein (Cas)-associated nucleases. This review explores the emerging gene and cell therapy strategies for rare pediatric genetic disorders. The success of gene therapy in treating genetic diseases depends on understanding the specific characteristics and function of the relevant gene, the genetic changes that cause disease, and the regulatory systems that affect gene expression. Rare pediatric neurogenetic diseases typically manifest early in life, lack specific treatment options, have high mortality rates, and present a significant threat to children's health and survival. A one-time genetic approach is desirable in many rare pediatric diseases and has been established only in a few pediatric diseases to date. Rare genetic diseases in childhood are an important factor as a healthcare concern due to high costs for the healthcare system, especially in gene therapy.

 

Author(s) Details

 Stefan Bittmann
Department of Pediatrics, Ped Mind Institute, Hindenburgring 4, D-48599 Gronau, Germany and Shangluo Vocational and Technical College, Shangluo, 726000, Shaanxi, China.

 

Please see the book here:- https://doi.org/10.9734/bpi/mbrao/v4/5688

No comments:

Post a Comment